


11/01/99



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gergory J. LaRosa

Application No.: 09/121,781

Group No. 1648

Filing Date: July 23, 1998

Examiner: R. Budens

Title: ANTI-CCR2 ANTIBODIES AND METHODS OF USE
THEREFOR

NOV 8 1999

TECH CENTER 1600/290

RECEIVED

NOV 12 1999

TECH CENTER 1600/2900

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231	
on <u>11/3/99</u>	<u>Marlene B. Fitch</u>
Date	Signature
<u>Marlene R. Fitch</u>	
Typed or printed name of person signing certificate	

#9a 4/18/00
TBray

TRANSMITTAL OF DUPLICATE SEQUENCE LISTING AND
PRELIMINARY AMENDMENT IN RESPONSE TO NOTICE TO COMPLY
WITH 37 C.F.R. §§1.821-1.825

Box Sequence Listing

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

This amendment is submitted in response to the Notice to Comply with Sequence Rules 37 C.F.R. §§1.821-1.825, mailed from the Patent Office on October 5, 1999, a copy of which is attached.

Transmitted herewith is a duplicate copy of the "Sequence Listing" (sheets 1/3 through 3/3) in paper form for the above-identified patent application as required by 37 C.F.R. §1.821(c) and a duplicate copy of the "Sequence Listing" in computer readable

A

form as required by 37 C.F.R. §1.821(e). As required by 37 C.F.R. §1.821(f), Applicant's Attorney hereby states that the content of the duplicate "Sequence Listing" in paper form and the duplicate computer readable form of the "Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter.


Applicant's Attorney notes that the Sequence Listing was originally submitted to the Patent Office on October 22, 1998, and received by the Patent Office on October 26, 1998, as evidenced by the attached copy of the date-stamped postcard receipt.

Applicant's Attorney submits the following amendments to comply with 37 C.F.R. §1.825:

In the Specification

Please insert the attached "Sequence Listing" (sheets 1/3 through 3/3), and comprising SEQ ID NOS: 1-8, into the above-referenced application.

Respectfully submitted,




Lisa M. Treannie
Attorney for Applicant
Registration No. 41,368
Telephone (781) 861-6240
Facsimile (781) 861-9540

Lexington, Massachusetts 02421-4799
Date: November 3, 1999

A

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):



- ☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821-1.825. Applicant's attention is directed to these regulations, published at 114 O. 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7. Other: _____

Applicant must provide:


- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact

For Rules Interpretation, call (703) 308-1123
 For CRF submission help, call (703) 308-4212
 For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.

A



COPY

DEB/HEW/LMT/mrf

LKS98-04

October 22, 1998

This is to acknowledge receipt of the following documents each filed under Certificate of Mailing Procedure 37 C.F.R. 1.8:

☒ Transmittal of ☒ Seq List ☐ Sub Seq List ☐ Pet Ext Time w/cpy
☐ Amendment Fee Letter w/copy ☐ Check for \$ _____
☒ SEQUENCE LISTING ☒ Paper ☒ CRF ☐ Auth to Charge Fees
☐ SUB SEQ LISTING ☐ Paper ☐ CRF ☐ Copy PTO-1533
☐ Copy of Notice to Comply
☐ Other _____

MAIL DATE CANCELLED

Applicant: Gregory J. LaRosa

Application No.: 09/121,781

Filed: July 23, 1998

Title: ANTI-CCR2 ANTIBODIES AND METHODS OF USE THEREFOR

Date received by the PTO:

A